• Corpus ID: 152507033

Understanding and Incentivizing Biosimilars

@article{Kanter2012UnderstandingAI,
  title={Understanding and Incentivizing Biosimilars},
  author={Jason Kanter and Robin C Feldman},
  journal={Hastings Law Journal},
  year={2012},
  volume={64},
  pages={57}
}
Congress recently passed the Biosimilars Act in an attempt to replicate the success that generic small molecule drugs have enjoyed under the Hatch-Waxman Act. The Biosimilars Act provides a pathway for biosimilars to achieve quicker and less expensive FDA approval than what is required for a new biopharmaceutical. There is, however, greater uncertainty and cost associated with achieving the coveted biosimilarity status. This reflects the complex production methods of biopharmaceuticals, along… 

Figures from this paper

An overview of biosimilars

This review attempt to highlight the differences between biosimilars and chemical generics, development stages, issues of concern with the use of biosimilar and need of appropriate regulations for their approval.

Biosimilar safety considerations in clinical practice.

Context is provided regarding key safety issues addressed in biosimilar development, approval, and delivery to inform oncologists on matters of safety to consider when prescribing biosimilars andinent issues about safety from countries or regions where biosimilARS are currently in use are reviewed.

Biosimilars in oncology: from development to clinical practice.

Education of physicians and other healthcare providers, payers, and patients about biosimilars may facilitate informed decision making, promote acceptance of biosimilar into clinical practice, increase accessibility, and expedite associated health and economic benefits.

Developing oncology biosimilars: an essential approach for the future.

Improved patient access to cancer therapies such as biologics and reducing healthcare costs are key initiatives of the US Government; the integration of approved biosimilars into clinical practice will be instrumental in accomplishing these goals.

Biosimilar safety factors in clinical practice.

Biosimilars: Rationale and current regulatory landscape.

  • E. Olech
  • Medicine
    Seminars in arthritis and rheumatism
  • 2016

A QUM partnership approach to regulating biosimilars in Australia

The National Medicines Policy could provide the necessary congruent framework and function for national and international regulation of biosimilars.

Inflammatory diseases: Integrating biosimilars into clinical practice.

  • S. Feldman
  • Medicine
    Seminars in arthritis and rheumatism
  • 2015

An overview of biosimilars

This mini-review covers the evolving international regulatory legislation for biosimilars, challenges for biosimilar development and expected developments.

References

SHOWING 1-9 OF 9 REFERENCES

Entry and Competition in Generic Biologics

It is found that generic biologics will have high fixed costs from clinical testing and from manufacturing, so there will be less entry than would be expected for generic pharmaceuticals.

"Generic Entry and the Pricing of Pharmaceuticals"

During the 1980s the share of prescriptions sold by retail pharmacies that was accounted for by generic products roughly doubled. The price response to generic entry of brand-name products has been a

The effect of generic competition on the price of brand-name drugs.

  • J. Lexchin
  • Medicine, Political Science
    Health policy
  • 2004

Role of glycosylation on the secretion and biological activity of erythropoietin.

Removal of any of the N-glycosylation sites reduced the in vivo but not the in vitro biological activity of the EPO molecule, which indicates that the O-linked carbohydrate is not essential for activity.

Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function.

Fractionation of cellular extracts demonstrated that the mutant proteins lacking glycosylation at each of these three sites, (38, 83, and 126) were associated mainly with membrane components or were degraded rapidly, and less than 10% ofThese three mutant proteins were processed properly and secreted from the cells.

See Frank & Salkever, supra note 124

    supra note 13, at 12 ("[B]ioavailability can be dramatically altered by subtle differences in glycoform distribution or other post-translation modifications

      Post-Translational Modifications in the Context of Therapeutic Proteins, 24 NATURE BIOTECH

      • 2006

      Post-Translational Modifications of Recombinant Proteins: Significance for Biopharmaceuticals, 39 MOLECULAR BIOTECH

      • 2008